- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01731730
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
January 14, 2015 updated by: Adynxx, Inc.
Study to Evaluate the Safety & Efficacy of a Single Intrathecal Pre-Operative Administration of AYX1 Injection at Two Dose Levels Compared to Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty (TKA)
The objectives of this proof of concept study are to evaluate the safety and preventive analgesic efficacy of a single preoperative intrathecal administration of AYX1 Injection in patients undergoing unilateral total knee arthroplasty.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Sheffield, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
Florida
-
Boynton Beach, Florida, United States
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States
-
-
Texas
-
Houston, Texas, United States
-
Nassau Bay, Texas, United States
-
Odessa, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Scheduled to undergo primary unilateral TKA for painful osteoarthritis
- American Society of Anesthesiologists Physical Status Classification System ≤ 3
- Medically stable as determined by the Investigator based on pre-study medical history, physical/neurological examination, clinical lab tests, and 12-lead ECG findings
- Body mass index of 18-40 kg/m2
- Stable medical regimen for ≥ 1 month before randomization
- Able to read and understand study instructions in English, and willing and able to comply with all study procedures
Exclusion Criteria:
- More than 2 other current focal areas of pain, none greater in intensity than the target knee and no other active chronic pain conditions that would compromise operative knee pain evaluation
- Inflammatory arthridities (i.e., rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis, gout)
- Operative arthroscopy in the surgical knee in the last 6 months, or other prior surgery in either knee in the last 12 months, except for diagnostic arthroscopy
- Planned use of any of the following for TKA: general endotracheal anesthesia (GETA), peripheral nerve block (i.e., femoral nerve block), neuroaxial (intrathecal or epidural) opioids postoperatively, or knee capsule injections
- Received aspirin within 1 week of randomization, or any nonsteroidal anti-inflammatory drug (NSAID) within 5 half-lives prior to randomization, or planned use of NSAIDS post-operatively through Day 28
- Use of more than 20 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization
- Use of adjuvant analgesics for chronic pain control (i.e., gabapentin, pregabalin) during the month prior to randomization or planned use post-operatively through Day 28
- Daily use of benzodiazepines in the 3 months prior to randomization (unless used for sleep and dosage will be consistent after surgery)
- Use of systemic corticosteroids (does not include inhaled steroids) within 3 months or intra-articular steroid injections within 1 month prior to randomization, or planned use of either post-op through Day 28
- Treatment with antibiotics or antivirals (EXCEPTION: topical treatments), immunosuppressives, antipsychotics, anticholinergics, or anticonvulsants within 1 month of randomization, with the exception of prescribed pre-surgical prophylactic antibiotics, and aspirin for cardiac prophylaxis (as long as discontinued within 1 week of randomization
- Current neurologic disorder, which could confound the assessment of pain (i.e., Parkinson's, Multiple Sclerosis)
- Current active depression symptoms
- Has had a change in dose or regimen of SSRIs or SNRIs for depression within 1 month of randomization
- Mini Mental State Exam score < 24 at screening
- Current history of insulin dependent diabetes mellitus, or autoimmune conditions
- Severe chronic obstructive or restrictive pulmonary disease, current diagnosis of obstructive sleep apnea documented by a sleep laboratory study, or current home use of continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BIPAP)
- Current evidence of alcohol abuse or history of alcohol-related complications within 1 year of randomization
- Known or suspected history of illicit drug abuse within 1 year before randomization, current or planned use of medical marijuana, or history of opioid dependence within 2 years before randomization
- Any malignancy within the past year, with the exception of basal cell carcinoma or uncomplicated or stable skin cancers documented to not require further or immediate treatment
- Women who are pregnant or nursing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo (Vehicle) Injection
Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
|
3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
|
Experimental: AYX1 Injection 110 mg
Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
|
3mL solution for intrathecal injection with 110 mg of AYX1
|
Experimental: AYX1 Injection 330 mg
Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
|
3mL solution for intrathecal injection with 330 mg of AYX1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain with walking during 5 meter walk test
Time Frame: 0-48 hours after surgery
|
Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 5 meter walk test during inpatient stay 0-48 hours
|
0-48 hours after surgery
|
Pain with walking during 15 meter walk test
Time Frame: From hospital discharge to Day 28
|
Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 15 meter walk test during outpatient period up to Day 28
|
From hospital discharge to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total use of opioid medications (morphine equivalents) during hospital stay
Time Frame: 0-48 hours after surgery
|
0-48 hours after surgery
|
|
Total use of opioid medications (morphine equivalents) post-discharge to Day 28
Time Frame: From hospital discharge to Day 28
|
From hospital discharge to Day 28
|
|
Pain with 45 degrees of knee flexion
Time Frame: 0-48 hours after surgery
|
Mean pain rating on the Numerical Rating Scale (NRS) for 45 degrees active knee flexion
|
0-48 hours after surgery
|
Pain with 90 degrees of knee flexion
Time Frame: From 7 to 28 days after surgery
|
Mean pain rating on the Numerical Rating Scale (NRS) for 90 degrees active knee flexion
|
From 7 to 28 days after surgery
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Brief Pain Inventory functional interference scores at Days 7, 14, 21, 28, and 42
Time Frame: 7 to 42 days after surgery
|
7 to 42 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Donald C Manning, MD, PhD, Adynxx, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
November 19, 2012
First Submitted That Met QC Criteria
November 19, 2012
First Posted (Estimate)
November 22, 2012
Study Record Updates
Last Update Posted (Estimate)
January 27, 2015
Last Update Submitted That Met QC Criteria
January 14, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADYX-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postsurgical Pain
-
Queen Mary University of LondonBarts & The London NHS TrustRecruitingPersistent Postsurgical PainUnited Kingdom
-
University of California, San DiegoRecruiting
-
Taiwan Liposome CompanyNot yet recruitingPostsurgical Pain Management
-
Shanghai Hengrui Pharmaceutical Co., Ltd.CompletedPostsurgical Pain ManagementChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.CompletedPostsurgical Pain ManagementChina
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Tampere University HospitalCompletedChronic Postsurgical PainFinland
-
Purdue Pharma LPTerminatedPostsurgical Pain Due to Third Molar ExtractionUnited States
-
Chinese PLA General HospitalPeking University People's Hospital; Sun Yat-sen University; Fudan University; The... and other collaboratorsCompletedPotassium, Decreased Level | Postsurgical Pain, ChronicChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
Clinical Trials on Placebo Injection
-
Beijing Tiantan HospitalCompleted
-
Beijing Tiantan HospitalActive, not recruitingAcute Ischemic StrokeChina
-
Harvest TechnologiesCompletedCritical Limb IschemiaUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Vifor Fresenius Medical Care Renal PharmaTigermed Consulting Co., LtdActive, not recruiting
-
Shanghai Yinnuo Pharmaceutical Technology Co.,...Active, not recruiting
-
PhaseBio Pharmaceuticals Inc.CompletedType 2 Diabetes MellitusUnited States
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingOverweight and ObesityChina
-
Beijing Kanova Biopharmaceutical Co., LTDNot yet recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting